A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Monotherapy and in Combination With Chemotherapy in Japanese Patients With Advanced Solid Tumours
Latest Information Update: 27 Jul 2022
At a glance
- Drugs Adavosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Jul 2022 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Planned End Date changed from 15 Jul 2021 to 5 Jan 2023.
- 13 Dec 2021 Planned primary completion date changed from 15 Jul 2021 to 5 Jan 2023.